Abeona Therapeutics® Announces Participation In Upcoming Investor Conferences
- Stifel 2026 Healthcare Conference: Fireside chat on Wednesday November 11, 2026, at 8:40 AM Eastern Time (ET) and investor meetings.
Jefferies Global Healthcare Conference: Presentation on Wednesday, November 18, 2026, at 10:30 AM Greenwich Mean Time (GMT) and investor meetings.
Live webcasts of the fireside chat and Company presentation can be accessed on the Investors section of the Abeona website under“Events” at , where replays of available events will also be accessible for a limited time.
About Abeona Therapeutics
Abeona Therapeutics Inc. is a commercial-stage biopharmaceutical company building a portfolio of therapies for rare and serious diseases with multiple opportunities for value creation. The Company's portfolio includes ZEVASKYN® (prademagene zamikeracel), the first and only autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa; ABO-801, a Phase 3-ready product candidate for eosinophilic esophagitis; and ABO-701 (PSMA-SIR-TTM), an investigational engineered T-cell therapy targeting PSMA. For more information, visit .
ZEVASKYN®, Abeona Assist®, Abeona Therapeutics®, and their related logos are trademarks of Abeona Therapeutics Inc.
CONTACT: Contacts: Investor and Media: Greg Gin VP, Investor Relations and Corporate Communications Abeona Therapeutics... Investor: Lee M. Stern Meru Advisors...
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept any
responsibility or liability for the accuracy, content, images, videos,
licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright issues
related to this article, kindly contact the provider above.
Comments
No comment